AR062051A1 - 2-fenilindoles como antagonistas del receptor de la prostaglandina d₂ - Google Patents
2-fenilindoles como antagonistas del receptor de la prostaglandina d₂Info
- Publication number
- AR062051A1 AR062051A1 ARP070103291A ARP070103291A AR062051A1 AR 062051 A1 AR062051 A1 AR 062051A1 AR P070103291 A ARP070103291 A AR P070103291A AR P070103291 A ARP070103291 A AR P070103291A AR 062051 A1 AR062051 A1 AR 062051A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenylethyl
- diseases
- dichloro
- methoxy
- methyl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- -1 but not limited to Chemical compound 0.000 abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 239000000460 chlorine Substances 0.000 abstract 3
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 208000003251 Pruritus Diseases 0.000 abstract 2
- 208000024780 Urticaria Diseases 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 230000007803 itching Effects 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000000940 2-methoxyphenyl ethyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 206010002199 Anaphylactic shock Diseases 0.000 abstract 1
- 240000007124 Brassica oleracea Species 0.000 abstract 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 abstract 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 abstract 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 abstract 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010038848 Retinal detachment Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 201000008736 Systemic mastocytosis Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 208000008423 pleurisy Diseases 0.000 abstract 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
- 230000004264 retinal detachment Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000006748 scratching Methods 0.000 abstract 1
- 230000002393 scratching effect Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82030206P | 2006-07-25 | 2006-07-25 | |
| US82030106P | 2006-07-25 | 2006-07-25 | |
| US82029906P | 2006-07-25 | 2006-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062051A1 true AR062051A1 (es) | 2008-08-10 |
Family
ID=38610820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103291A AR062051A1 (es) | 2006-07-25 | 2007-07-24 | 2-fenilindoles como antagonistas del receptor de la prostaglandina d₂ |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20090176804A1 (enExample) |
| EP (1) | EP2066628B1 (enExample) |
| JP (1) | JP2009544721A (enExample) |
| KR (1) | KR20090039735A (enExample) |
| AR (1) | AR062051A1 (enExample) |
| AT (1) | ATE485270T1 (enExample) |
| AU (1) | AU2007276885A1 (enExample) |
| BR (1) | BRPI0714554A2 (enExample) |
| CA (1) | CA2659055A1 (enExample) |
| CL (1) | CL2007002163A1 (enExample) |
| CO (1) | CO6190511A2 (enExample) |
| CR (1) | CR10577A (enExample) |
| DE (1) | DE602007010010D1 (enExample) |
| DK (1) | DK2066628T3 (enExample) |
| EC (1) | ECSP099087A (enExample) |
| GT (1) | GT200900016A (enExample) |
| IL (1) | IL196587A0 (enExample) |
| MA (1) | MA30643B1 (enExample) |
| MX (1) | MX2009000830A (enExample) |
| NO (1) | NO20090862L (enExample) |
| PE (1) | PE20080549A1 (enExample) |
| PT (1) | PT2066628E (enExample) |
| TN (1) | TNSN08515A1 (enExample) |
| TW (1) | TW200821286A (enExample) |
| WO (1) | WO2008014186A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009072576A1 (ja) * | 2007-12-04 | 2009-06-11 | Sapporo Breweries Limited | 骨形成促進剤 |
| DK2346819T3 (da) * | 2008-11-17 | 2013-05-13 | Hoffmann La Roche | Naphthyleddikesyre |
| BR112012024114B1 (pt) | 2010-03-22 | 2021-02-09 | Idorsia Pharmaceuticals Ltd | Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica |
| JP5964945B2 (ja) | 2011-04-14 | 2016-08-03 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用 |
| EP2912458B1 (en) | 2012-10-24 | 2018-07-18 | NYU Winthrop Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| JP2015089886A (ja) * | 2013-11-06 | 2015-05-11 | 国立大学法人名古屋大学 | 嵩高い置換基を有する化合物を用いた植物成長調整剤 |
| TWI649321B (zh) | 2014-03-17 | 2019-02-01 | 瑞士商愛杜西亞製藥有限公司 | 氮雜吲哚乙酸衍生物及彼等作為前列腺素ｄ２受體調節劑之用途 |
| WO2015140701A1 (en) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| AU2016323262B2 (en) | 2015-09-15 | 2020-11-19 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
| JP2020533595A (ja) | 2017-09-13 | 2020-11-19 | プロジェニティ， インコーポレイテッド | 子癇前症バイオマーカならびに関連するシステムおよび方法 |
| US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| EP3759073A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Sulfonamide derivates as nlrp3 inhibitors |
| EP3759103A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| EP3759078A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166627A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| JP7455762B2 (ja) * | 2018-05-09 | 2024-03-26 | グルソックス・バイオテック・アーベー | 選択的なＮｏｘ阻害活性を有する新規のスルホンアミド誘導体 |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| CN111333516B (zh) * | 2020-04-14 | 2022-09-06 | 国药集团化学试剂有限公司 | 一种2-氯-5-溴硝基苯的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2006000016A (es) * | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
-
2007
- 2007-07-20 AU AU2007276885A patent/AU2007276885A1/en not_active Abandoned
- 2007-07-20 PT PT07799729T patent/PT2066628E/pt unknown
- 2007-07-20 DE DE602007010010T patent/DE602007010010D1/de active Active
- 2007-07-20 CA CA002659055A patent/CA2659055A1/en not_active Abandoned
- 2007-07-20 MX MX2009000830A patent/MX2009000830A/es active IP Right Grant
- 2007-07-20 EP EP07799729A patent/EP2066628B1/en active Active
- 2007-07-20 BR BRPI0714554-3A patent/BRPI0714554A2/pt not_active IP Right Cessation
- 2007-07-20 DK DK07799729.4T patent/DK2066628T3/da active
- 2007-07-20 JP JP2009521914A patent/JP2009544721A/ja not_active Abandoned
- 2007-07-20 WO PCT/US2007/073945 patent/WO2008014186A1/en not_active Ceased
- 2007-07-20 AT AT07799729T patent/ATE485270T1/de active
- 2007-07-20 KR KR1020097001687A patent/KR20090039735A/ko not_active Abandoned
- 2007-07-23 PE PE2007000951A patent/PE20080549A1/es not_active Application Discontinuation
- 2007-07-24 AR ARP070103291A patent/AR062051A1/es not_active Application Discontinuation
- 2007-07-24 CL CL200702163A patent/CL2007002163A1/es unknown
- 2007-07-25 TW TW096127005A patent/TW200821286A/zh unknown
-
2008
- 2008-12-12 TN TNP2008000515A patent/TNSN08515A1/en unknown
-
2009
- 2009-01-15 CO CO09002745A patent/CO6190511A2/es not_active Application Discontinuation
- 2009-01-19 IL IL196587A patent/IL196587A0/en unknown
- 2009-01-21 CR CR10577A patent/CR10577A/es not_active Application Discontinuation
- 2009-01-22 US US12/357,725 patent/US20090176804A1/en not_active Abandoned
- 2009-01-23 GT GT200900016A patent/GT200900016A/es unknown
- 2009-01-23 EC EC2009009087A patent/ECSP099087A/es unknown
- 2009-02-13 MA MA31635A patent/MA30643B1/fr unknown
- 2009-02-24 NO NO20090862A patent/NO20090862L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE485270T1 (de) | 2010-11-15 |
| DE602007010010D1 (de) | 2010-12-02 |
| CL2007002163A1 (es) | 2008-02-08 |
| MX2009000830A (es) | 2009-02-03 |
| DK2066628T3 (da) | 2011-02-07 |
| IL196587A0 (en) | 2009-11-18 |
| US20090176804A1 (en) | 2009-07-09 |
| CO6190511A2 (es) | 2010-08-19 |
| CR10577A (es) | 2009-03-20 |
| WO2008014186A1 (en) | 2008-01-31 |
| TW200821286A (en) | 2008-05-16 |
| EP2066628B1 (en) | 2010-10-20 |
| AU2007276885A1 (en) | 2008-01-31 |
| PT2066628E (pt) | 2010-12-31 |
| TNSN08515A1 (en) | 2010-04-14 |
| KR20090039735A (ko) | 2009-04-22 |
| PE20080549A1 (es) | 2008-06-20 |
| ECSP099087A (es) | 2009-02-27 |
| GT200900016A (es) | 2010-10-13 |
| MA30643B1 (fr) | 2009-08-03 |
| JP2009544721A (ja) | 2009-12-17 |
| EP2066628A1 (en) | 2009-06-10 |
| CA2659055A1 (en) | 2008-01-31 |
| BRPI0714554A2 (pt) | 2013-05-07 |
| NO20090862L (no) | 2009-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062051A1 (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d₂ | |
| ECSP088813A (es) | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 | |
| TNSN07251A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| AU2017356214B2 (en) | Heterocyclic modulators of lipid synthesis | |
| US20230405016A1 (en) | Heterocyclic modulators of lipid synthesis | |
| UA88485C2 (en) | 2,6-substituted-4-monosubstituted amino-pyrimidines as prostaglandin d2 receptor antagonists | |
| TW200634015A (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders | |
| CA2881699A1 (en) | 3-aminocycloalkyl compounds as rorgammat inhibitors and uses thereof | |
| TNSN08131A1 (en) | Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist | |
| TW200911817A (en) | Polycyclic guanine derivatives and methods of use thereof | |
| PH12018500533A1 (en) | Pyrazolyl-substituted heteroaryls and their use as medicaments | |
| WO2010084402A3 (en) | Heterocyclic compounds as phosphodiesterase inhibitors | |
| NO20084564L (no) | Stramme "Constrained" forbindelser som CGRP-reseptor antagonister | |
| UA88795C2 (ru) | Гетероциклические соединения, которые применяются для лечения воспалителных и аллергических нарушений | |
| JP6609253B2 (ja) | シアノチオフェン誘導体 | |
| UA95303C2 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| DOP2009000009A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| TH100504B (th) | อินโดลคาร์บอกซาไมด์เป็นสารยับยั้ง ikk2 | |
| TH100504A (th) | อินโดลคาร์บอกซาไมด์เป็นสารยับยั้ง ikk2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |